Onconic Therapeutics

At a glance

Onconic Therapeutics filed 64 disclosures in the last 12 months, including 16 insider and 2 5% holder. The most recent key filing was on Jul 3.

The 2025 annual report lists 38 employees with an average tenure of 1.9 years and average pay of ₩78.6M. Its 5 directors and auditors were paid ₩185.9M each on average. It paid no cash dividend for 2025. 제일약품(주) and related parties held 52.07% at year end.

From the 2025 annual report

Staff: 38 (14 men, 24 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩3B. Directors and auditors: 5, paid ₩929.3M in total.

No cash dividend was paid for 2025.

Largest shareholder

제일약품(주) holds 44.95%; with 4 related parties the group holds 52.07% of common shares at year end (from 52.80% at the start of the year).

Individuals paid ₩500M or more

Auditor: 한영회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary